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Summary Reactivity of the monoclonal antibody 791T/36 with secondary malignant deposits has been
investigated in frozen sections of 74 human liver biopsy specimens. There was no reactivity with hepatocytes
but in some instances binding to fibrous tissues and in one case to portal tract lymphocytes was observed.
Sections from 9 biopsy specimens contained malignant deposits. In seven of these 791T/36 bound either to
malignant cells or to pseudoacinar contents (3 colorectal adenocarcinomas; 1 probable pancreatic adeno-
carcinoma; 1 medullary cell carcinoma of thyroid; 1 oat cell carcinoma of bronchus and 1 deposit of nodular
selerosing Hodgkins Disease). Two undifferentiated tumours (1 gastric adenocarcinoma and 1 oat cell
bronchial carcinoma) showed no antibody binding.
The histological pattern of reactivity previously reported with primary tumours appears to be similar in
secondary deposits. A wider range of tumours than recognised hitherto binds 791T/36. Whether the binding
to fibrous tissue seen in some instances is sufficient to cause diagnostic uncertainty when 791T/36 is used for
scanning requires further investigation.
The monoclonal antibody 791T/36 originally raised
against an osteogenic sarcoma cell line (Embleton
et al., 1981) has been shown to react with
malignant cells of other primary tumours including
those arising in colon, lung and ovary (Farrands et
al., 1981, 1982; Ballantine et al., 1985; Durrant et
al., 1986a,b). It displays weak or no reactivity with
cells from normal tissue (Campbell et al., 1984).
The epitope recognised by 791T/36 is expressed on
a glycoprotein of apparent molecular weight 72,000
which is found in several human tumour cell lines
(Campbell et al., 1984). It is detectable on the cell
surface (Durrant et al., 1986a) and stroma
(Armitage et al., 1984) of human colorectal
tumours or tumour cell lines. The antibody 791T/36
does not react with the carcinoembryonic antigen
(Durrant et al., 1986a).
In man, radiolabelled 791T/36 has been used to
image primary oesteogenic sarcoma and colorectal
cancers (Farrands et al., 1982, 1983; Armitage et
al., 1984, 1985). In some cases these studies have
demonstrated that the antibody can also image
secondary tumour deposits in the brain and liver
(Armitage et al., 1984; Ballantyne et al., 1985).
When conjugated to cytotoxic drugs such as metho-
trexate, 791T/36 can exert selective antibody-
directed cytotoxicity in vitro against tumour cell
lines (Embleton et al., 1983; Garnett et al., 1983).
These observations suggest that 791T/36 may have
Correspondence: C.J. Hawkey.
Received 7 March 1986; and in revised form 28 July 1986.
therapeutic potential, not only in the treatment of
primary tumours but also in the control of
disseminated disease. Before the latter possibility
can be explored in more depth, it is necessary to
examine the reactivity of the antibody with
metastatic deposits of tumour cells, especially those
present in the liver, a frequent site of metastatic
spread. In this paper we describe the reactivity of
791T/36 with histological sections of liver biopsy
specimens with and without metastases from colo-
rectal and other primary malignancies.
Materials and methods
HistologicaltClinical assessment
Human liver tissue was obtained by percutaneous
or peroperative needle biopsy. Most biopsy
specimens were obtained during the course of
clinical management. In addition, normal liver was
obtained at cholecystectomy, with the approval of
the South Nottingham Ethical Committee and the
informed consent of the patient.
After excision, each biopsy was bisected. One
half was fixed in formal saline and embedded for
histological assessment. The other half was snap-
frozen for the examination of antibody staining (see
below). The biopsy specimens were classified on the
basis of histological diagnosis in the context of
clinical presentation.
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Immunoperoxidase staining technique
The second half of each biopsy was frozen in
isopentane (2 methyl butane) cooled by liquid
nitrogen, and stored at -180°C. Reactivity of
791T/36 with 5,um frozen sections was assessed by
an indirect immunoperoxidase technique as
previously described (Holmes et al., 1983).
Antibody 791T/36 was used in the form of
undiluted tissue culture supernatant. Sections were
successively incubated for 30min with:
(a) 791T/36
(b) rabbit antimouse immunoglobulin (Dako
immunoglobulins A/S Copenhagen, Denmark)
diluted to 1/1000 (v/v) with Tris/saline (pH 7.6)
(c) swine anti-rabbit immunoglobulin (Dako)
diluted to 1/80 (v/v) with Tris/saline
(d) rabbit peroxidase - anti-peroxidase complex
(Dako) diluted to 1/80 (v/v) with Tris/saline.
Normal human serum (10%) was added to the
rabbit anti-mouse immunoglobulins in order to
block non-specific binding of immunoglobulins to
the tissue sections. The positive controls used were
primary colorectal tumours already known to react.
Negative controls included sections processed either
in the absence of primary antibody or in the
presence of other monoclonal antibodies known to
be unreactive with elements of normal or malignant
liver tissue.
Assessment ofantibody staining
For each liver biopsy antibody staining was
assessed by comparison with positive and negative
controls included in each test. Reactivity was
graded as negative (0), positive (+) or as strongly
positive (+ +).
Results
A total of 74 biopsy specimens was studied. Sixty-
five of these were from patients with normal liver
tissue or a variety of non-malignant diseases. In
none of these cases was there significant reactivity
with hepatocytes. However, fibrous tissue in the
portal tracts of 26 biopsy specimens showed definite
staining (13 normal, 6 chronic hepatitis, 2 cirrhosis,
2 alcoholic liver disease, 2 primary biliary cirrhosis,
1 secondary biliary cirrhosis). In one biopsy specimen
obtained from a patient with chronic active hepatitis
there was intense reactivity with lymphocytes in the
portal tract. In 11 cases there was reactivity at the
sinusoidal edge of hepatocytes consistent with
binding to stromal elements in the Disse space (4
normal, 3 chronic hepatitis, 2 primary biliary
cirrhosis, 2 alcoholic liver disease) (Figure 1). Seven
of these also had reactive fibrous tissue in the portal
tracts as described above.
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Figure 1 Normal liver biopsy showing reactivity with
stromal elements in the Disse space but no binding to
hepatocytes ( x490).
Nine biopsy specimens contained secondary
deposits (Table I). There were 5 adenocarcinomas
of gastro-intestinal origin and 3 of these exhibited
significant staining of tumour cells. In one case all
tumour cells were strongly reactive. In the second
case both reactive and non-reactive tumour cells
were observed (Figure 2). In the third case all the
malignant cells reacted but the extent of this
reactivity varied from very weak to intense
(Figure 3). In two specimens where the metastatic
deposits were of gastro-intestinal origin, the tumour
cells themselves showed no reactivity. In one of
these however, there was significant reactivity with
the tumour stroma (Figure 4). All tumours of colo-
rectal origin showed cellular or stromal reactivity as
previously shown for primary tumours (Armitage et
al., 1984).
There were four specimens containing secondary
deposits which were not of gastro-intestinal origin
(Table I). One of these was a metastatic tumour
arising from medullary cell carcinoma of the
thyroid which had been excised 22 years previously
(Figure 5). Both cellular and stromal elements of
this tumour showed intense reactivity with 791T/36
and this was exploited to obtain a positive scan
corresponding to palpable tumour deposits in the
liver of this patient (Figure 6).
Of two undifferentiated bronchial small cell
carcinomas, one was reactive and one was not. In a
case of Hodgkins disease (nodular sclerosing) the
antibody showed reactivity with the stroma and
some of the cellular infiltrate.ANTI-TUMOUR MONOCLONAL ANTIBODY 873
Table I Reactivity of 791T/36 with tumour metastases
Reactivityb
Case no. Age Sex Diagnosis Differentiationa Cells Stroma
1 60 M Pancreatic adenocarcinoma 2 +/0
(probable)
2 58 M Colonic adenocarcinoma 1 + + + +
3 66 M Colonic adenocarcinoma 1 +/0 -
4 69 F Rectal adenocarcinoma 1 0 + +
5 60 F Gastric adenocarcinoma 0 0
6 39 M Medullary cell carcinoma 2 + + + +
of thyroid
7 62 M Bronchus oat cell 0 +
8 55 F Bronchus oat cell 0 0
9 55 F Hodgkins Disease 1 +/0 +
aDifferentiation: 0 undifferentiated, 1 =moderately differentiated, 2=well differentiated. bReactivity of
791: + + =strongly reactive, + =reactive, 0=unreactive, +/0 = some cells reactive, others unreactive,
- =not present in section examined.
Figure 2 Colonic adenocarcinoma deposit in liver
showing avid reactivity with some tumour cells but no
binding to others. Liver tissue (above and below)
shows no reactivity (x 126).
Figure 3 Adenocarcinoma liver deposits showing
binding to all cells; intensity varies from weak to
intense ( x 730).
Figure 4 Rectal adenocarcinoma showing intense
reactivity with tumour stroma. Malignant cells are
however all unreactive ( x 315).
Figure 5 Medullary cell carcinoma of thyroid. All
cells show intense cytoplasmic binding. Note also
reactivity with stroma between cells ( x 315).874 C.J. HAWKEY et al.
Figure 6 Anterior view of the liver recorded with a
large field of view gamma camera, medullary cell
carcinoma of the thyroid. '33-labelled 791T/36
(75 MBq) was used to obtain the scan 48h after
injection. The image shown is of activity remaining
after digital image substraction of a 99' TC-labelled
red blood cell and free pertechnetate (200MBq) scan
used to simulate blood pool distribution. Most activity
is in the right lobe of the liver and corresponds to
palpable tumour mass from which the liver biopsy
specimen was obtained.
Discussion
These data show that 791T/36 reacts with
metastatic deposits of some but not all gastro-
intestinal tumours. The pattern of reactivity seen in
primary colorectal tumours (Farrands et al., 1982;
Armitage et al., 1984) appears to be preserved in
secondary deposits. Our observations show that
other gastro-intestinal tumours, as well as an oat
cell carcinoma of the bronchus, medullary cell
carcinoma of the thyroid and a Hodgkins
lymphomatous deposit also reacted. With the latter
two both tumour cells and stroma were reactive. In
two cases (1 gastric adenocarcinoma, 1 oat-cell
carcinoma) however there was no reactivity with
791T/36. This may, in part, reflect the
undifferentiated nature of both these tumours.
These data can be interpreted in the light of
earlier studies of reactivity of 791T/36 with primary
tumours. The majority of colorectal adeno-
carcinomas bind 791T/36, particularly to the
pseudoacinar contents and/or the tumour stroma
(Farrands et al., 1982; Armitage et al., 1984). In the
present study this pattern was also seen with
secondary deposits. Primary tumours arising
elsewhere in the gastrointestinal tract rarely show
any reactivity with 791T/36 (Armitage et al., 1984).
The single gastric adenocarcinoma in the present
study also showed no reactivity. Thus our data
suggest that the pattern of reactivity for secondary
deposits mirrors that seen in primary tumours.
Further study is needed to determine with certainty
whether there are any changes in the pattern or
extent of antigenic expression associated with
tumour dissemination.
The fact that binding occurred to a wide range of
tumours (including, in our study, medullary cell
carcinoma of the thyroid, an oat cell carcinoma
and an example of Hodgkins disease) shows that
791T/36 reacts with an antigen present in a wide
range of tumours. It is not, however, a universal
cancer-associated antigen and its identity and
biological significance are at present unknown.
Binding to the stromal elements of a tumour may
occur independently of its malignancy. Reactivity
with the stroma of colonic adenocarcinomas and
with collagen fibres in normal colonic submucosal
tissue has been previously reported (Farrands et al.,
1982; Armitage et al., 1984). Our study shows that
this is also true of fibrous tissue in the liver and a
variety of metastases including those from colon
and medullary cell carcinoma of the thyroid.
The reactivity with the deposit of Hodgkins
disease is open to several interpretations. As with
colonic adenocarcinomas and the medullary cell
carcinoma of the thyroid, reactivity with the fibrous
elements does not necessarily reflect its malignancy.
The same may be true of its reactivity with the
cellular components. It is difficult to be certain of
the origin of those cells which are reactive because
of the difficulties of identification in frozen section,
but it is possible that binding reflects their
lymphoid origin rather than malignancy.
These data have several clinical implications.
Where radio-labelled 791T/36 is used as an imaging
agent it seems likely that some tumours will not be
shown. However, colorectal tumours which have
metastasised are reactive with 791T/36 and the
main use of 791T/36 for imaging would appear to
be scanning for these tumours. We have shown that
a scan of a medullary cell carcinoma can be
obtained. More data will be required to establish
the value of 791T/36 for tumours not of colorectal
origin since not all are reactive. Likewise the role of
791T/36 as a vehicle for chemotherapeutic drugs or
therapeutic radionuclides seems likely to be
restricted to use with reactive tumours.
791T/36 lacks absolute discrimination in two
respects. Firstly, it reacts with the stromal elements
in both normal liver and tumour deposits.
Secondly, binding to portal tract lymphocytes was
observed in one case; this observation is of interest
in the light of earlier data suggesting that 791T/36
binds to mitogen stimulated lymphocytes (Price et
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al., 1983). Both these limitations on the selectivity
of 791T/36 are important. Diagnostically, confusion
might arise when 791T/36 is used as the basis of
radionuclide scanning techniques if it attaches to
non-tumour elements. Likewise, liver stroma or
lymphocytes represent potential undesired targets
for antibody linked chemotherapeutic agents or
therapeutic radionuclides. In some colorectal
tumours the stroma and pseudoacini appear to
react more strongly than the tumour cell cytoplasm
(as with primary tumours): it remains to be seen
whether this has a singificant impact on the
potency or specificity of chemotherapeutic or radio-
nuclide agents attached to 791T/36. Our data
suggest that these are critical questions to be
answered by further research before 791T/36 fulfils
its promise in the diagnosis and treatment of dis-
seminated cancers.
We thank Mr W. Breckenbury for expert black and white
photomicrography.
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